Kate Therapeutics
Jana Jenquin has a diverse background in biochemistry and molecular biology, with experience ranging from being a Senior Scientist at Kate Therapeutics to owning Jenquin Consulting. Jenquin has held positions as a Research Scholar at University at Albany, a Postdoctoral Research Fellow at the University of Florida College of Medicine, and a Graduate Student at the University of Oregon. With a Ph.D. in Biochemistry and Molecular Biology, Jenquin has also worked as a Research Chemist at OMIC USA Inc. and as a Lab Technician I at the American Red Cross.
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.